The rapid adoption of AI in digital health is improving access and workflow, but insurance frameworks have not kept pace. Companies face exposures that traditional policies were not designed to address, leaving founders, investors, and insurers to reconcile innovation with unclear risk transfer.
The Unseen Liabilities: What’s Really Driving Claims?
Public attention often centers on cyberattacks, yet claims data tells a different story. The primary loss drivers are medical negligence and improper supervision tied to AI-assisted care. When an algorithm contributes to a clinical error, a single patient event can cascade into claims across multiple lines: professional liability for the clinician, errors and omissions for the software vendor, and cyber or privacy claims if data or model failings are implicated. This “liability chain” multiplies cost and complexity because each link may point at another party for fault, producing contested coverage fights and longer payouts. For investors and executives that means exposure is more operational and clinical than purely technical, and remediation requires both legal clarity and process controls around model deployment, monitoring, and human oversight.
Market Shift: Demand for Clarity and Comprehensive Coverage
Insureds are shifting priorities. Speed and quality of claims handling now outrank price in purchasing decisions. Firms want policies that explicitly state whether AI is covered, and under what conditions. “Silent AI exposure”—policies that neither include nor exclude AI risks—is a growing source of uncertainty. That ambiguity raises the prospect of denied claims and uninsured losses. Insurers that update wording across professional liability, cyber, and technology lines will reduce friction and capture market share. For digital health companies, aligning risk management with observed loss patterns means mapping AI functions to policy triggers, documenting supervision protocols, and insisting on express AI endorsements or exclusions where appropriate.
Strategic actions include clarifying contractual indemnities with partners, investing in clinical governance and model surveillance, and engaging brokers and underwriters early. For investors, consider carrier capacity and policy language as part of diligence. For insurers, there is opportunity to design products that price and underwrite AI-enabled clinical risk sensibly while promoting safer deployments.
